Completes business combination with Lakeshore Acquisition I Corp. ProSomnus common stock will trade on Nasdaq Capital Market under ticker symbol "OSA" SAN FRANCISCO, Dec. 06, 2022 (GLOBE NEWSWIRE) --  ProSomnus, Inc. ("the Company"), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the completion of its previously announced business combination with Lakeshore Acquisition I Corp. ("Lakeshore") (NASDAQ:LAAA), a publicly traded special purpose acquisition company. ProSomnus will commence trading on the Nasdaq Global Market under the symbol "OSA" on Dec. 7, 2022. The business combination, which was approved by Lakeshore's shareholders

SAN FRANCISCO, Dec. 2, 2022 /PRNewswire/ -- Lakeshore Acquisition I Corp. (NASDAQ:LAAA) ("Lakeshore") today announced that its shareholders have approved all proposals related to the previously announced business combination (the "Business Combination") with ProSomnus Holdings, Inc. ("ProSomnus") at a special meeting of shareholders held on December 2, 2022. Approximately 92.4% of the votes cast at the meeting on the Business Combination proposal, representing approximately 80.5% of Lakeshore's outstanding shares, voted to approve the Business Combination. The closing of the Business Combination is anticipated to occur on or about December 6, 2022.  Following the closing, the combined compan

Generated record quarterly revenues, and expects merger with Lakeshore Acquisition I Corp. to close in the fourth quarter of 2022 Company Updates 2022 Revenue Guidance to range of $19.0 - $19.5 million for full year 2022 SAN FRANCISCO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- ProSomnus ("the Company"), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea ("OSA"), today announced results for the third quarter ended September 30, 2022 and provided a business update. Recent Highlights Record revenues for the first nine months of 2022 of $13.6 million, a 40.6% year-over-year. Revenues in the third quarter were $5.0 million, also a record.Gross margins for the first

Device expands ProSomnus' suite of FDA-cleared Precision Oral Appliance Therapy Devices for treatment of Obstructive Sleep Apnea (OSA) Device is engineered to provide Medicare beneficiaries and their healthcare providers with new options for treating OSA SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- ProSomnus ("the Company"), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the ProSomnus EVO™ [PH] Sleep and Snore Device. The device joins the Company's flagship product, the ProSomnus EVO™, in its line of FDA-cleared, patie

SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- ProSomnus Holdings Inc. ("ProSomnus"), the leader in patient preferred medical devices for the treatment of obstructive sleep apnea (OSA), today announced that Laing Rikkers, Executive Chairwoman and Co-Founder, is scheduled to participate at the Oppenheimer Private Company Showcase on October 17-18, 2022 at the Four Seasons in Palo Alto, California. Laing Rikkers will present at 10:25 am Pacific Time, and will be available for investor meetings throughout both days. About ProSomnusProSomnus is the first manufacturer of precision, mass-customized oral appliance therapy devices to treat OSA, which affects over 74 million Americans and is ass

SAN FRANCISCO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- ProSomnus, a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that the ProSomnus EVOTM Sleep and Snore Device is now reimbursable by Germany's public health insurance system. The ProSomnus EVO is an alternative to legacy oral devices and CPAP machines, and can result in more effective treatment and superior patient compliance. It repositions and stabilizes the jaw during sleep, improving airflow through a patient's pharyngeal space. The ProSomnus EVO consists of maxillary and mandibular aligner trays for orthodontic treatment that are precision-manufactured with twin-mated posts, and

SAN FRANCISCO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- ProSomnus ("the Company"), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that it has placed on Inc. Magazine's Inc. 5000 list of America's fastest-growing private companies for 2022. This marks the fourth consecutive year that ProSomnus has been included in the Inc. 5000 list. Companies on the 2022 Inc. 5000 list are ranked according to percentage revenue growth from 2018 to 2021. Inc. also ranks the fastest-growing companies by industry, metro area, revenue, and number of employees. "The entire ProSomnus team is honored to be featured on the Inc. 5000 list for the fourth consecu

SAN FRANCISCO, July 29, 2022 (GLOBE NEWSWIRE) -- ProSomnus, a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced it will host a first of its kind symposium focused on the shift toward emerging therapies for people diagnosed with OSA. Leading sleep medicine clinicians will discuss their clinical, practical, and scientific perspectives on precision oral appliance therapy as an option for patients diagnosed with OSA who refuse or fail CPAP, cannot access CPAP due to the recall, or simply prefer alternative treatment. The two-day event will offer 12 continuing education credit hours and take place at the Fairmont Hotel in San Francisco from

32,219-square-foot facility will quintuple growth and create local jobs All ProSomnus medical devices are made in Pleasanton, CA, USA SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- ProSomnus, a leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced plans for a new 32,219-square-foot facility in Pleasanton, California, USA. The facility will serve as the company's global headquarters and manufacturing center of excellence. The move will quintuple manufacturing capacity, enabling ProSomnus to meet the rapidly growing demand for the company's FDA-cleared oral appliance therapy devices. ProSomnus expects to begin operations at the fa

SAN FRANCISCO, June 3, 2022 /PRNewswire/ -- ProSomnus, a leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the results of three studies evaluating its FDA-cleared Oral Appliance Therapy (OAT) devices in the treatment of OSA. ProSomnus will share data in three poster presentations at SLEEP 2022, the Annual Meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held from June 4-8 in Charlotte, North Carolina. The data to be presented demonstrate the efficacy and performance advantages of precision oral appliance therapy, a new option for the treatment of OSA. ProSomnus is a pioneer in precision oral

25-NSE - Lakeshore Acquisition I Corp. (0001848000) (Subject)

8-K/A - Lakeshore Acquisition I Corp. (0001848000) (Filer)

8-K - Lakeshore Acquisition I Corp. (0001848000) (Filer)

425 - Lakeshore Acquisition I Corp. (0001848000) (Subject)

8-K - Lakeshore Acquisition I Corp. (0001848000) (Filer)

425 - Lakeshore Acquisition I Corp. (0001848000) (Subject)

8-K - Lakeshore Acquisition I Corp. (0001848000) (Filer)

425 - Lakeshore Acquisition I Corp. (0001848000) (Subject)

DEFM14A - Lakeshore Acquisition I Corp. (0001848000) (Filer)

10-Q - Lakeshore Acquisition I Corp. (0001848000) (Filer)

SC 13G/A - Lakeshore Acquisition I Corp. (0001848000) (Subject)

SC 13G/A - Lakeshore Acquisition I Corp. (0001848000) (Subject)

SC 13G - Lakeshore Acquisition I Corp. (0001848000) (Subject)

SC 13G - Lakeshore Acquisition I Corp. (0001848000) (Subject)

SC 13G - Lakeshore Acquisition I Corp. (0001848000) (Subject)